BioNTech SE (BNTX) Stock Chart
NasdaqGSView the BioNTech SE stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.
Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.
Read the BNTX trend first
Use the range controls to compare short-term moves with the longer-term BioNTech SE stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.
Check price with volume
Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.
Verify before acting
This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.
Key Statistics
Financial Metrics
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Related Charts
Data Definitions
Previous close
The most recent prior regular-session close reported by the market data source.
Day range
The source-reported high and low for the current or most recent trading session.
Volume
The number of shares, units, contracts, or asset quantity reported as traded during the period.
Moving averages
The 50-day and 200-day averages smooth recent prices to give quick trend context.
Market cap
A company or fund size estimate based on price and shares outstanding when source data is available.
P/E ratio
Price divided by earnings per share. It is most useful when compared with peers and growth expectations.